Compare · ISPC vs MEDP
ISPC vs MEDP
Side-by-side comparison of iSpecimen Inc. (ISPC) and Medpace Holdings Inc. (MEDP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ISPC and MEDP operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- MEDP is the larger of the two at $15.18B, about 4413.4x ISPC ($3.4M).
- Over the past year, ISPC is down 94.5% and MEDP is up 12.1% - MEDP leads by 106.6 points.
- MEDP has been more active in the news (5 items in the past 4 weeks vs 3 for ISPC).
- MEDP has more recent analyst coverage (25 ratings vs 2 for ISPC).
- Company
- iSpecimen Inc.
- Medpace Holdings Inc.
- Price
- $2.29-1.08%
- $535.63+0.74%
- Market cap
- $3.4M
- $15.18B
- 1M return
- -11.05%
- +17.55%
- 1Y return
- -94.54%
- +12.05%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2016
- News (4w)
- 3
- 5
- Recent ratings
- 2
- 25
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Latest ISPC
- Amendment: SEC Form S-1/A filed by iSpecimen Inc.
- iSpecimen Inc. filed SEC Form 8-K: Other Events
- Amendment: SEC Form S-1/A filed by iSpecimen Inc.
- SEC Form S-1 filed by iSpecimen Inc.
- SEC Form EFFECT filed by iSpecimen Inc.
- SEC Form S-3 filed by iSpecimen Inc.
- iSpecimen Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- iSpecimen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form DEFA14A filed by iSpecimen Inc.
- SEC Form D filed by iSpecimen Inc.
Latest MEDP
- Medpace downgraded by Robert W. Baird with a new price target
- Medpace downgraded by Jefferies with a new price target
- Director Mccarthy Cornelius P. Iii converted options into 28 shares, increasing direct ownership by 0.27% to 10,352 units (SEC Form 4)
- Director Kraft Robert O. converted options into 33 shares, increasing direct ownership by 4% to 955 units (SEC Form 4)
- Director Carley Brian T converted options into 36 shares, increasing direct ownership by 0.11% to 32,825 units (SEC Form 4)
- Medpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026
- New insider Hansman Brad W. claimed ownership of 697 shares (SEC Form 3)
- SEC Form 8-K filed by Medpace Holdings Inc.
- General Counsel & Corp. Secy. Ewald Stephen P exercised 16,349 shares at a strike of $138.87 and sold $7,357,050 worth of shares (16,349 units at $450.00) (SEC Form 4)
- SEC Form 8-K filed by Medpace Holdings Inc.